לקנמב (Hebrew Wikipedia)

Analysis of information sources in references of the Wikipedia article "לקנמב" in Hebrew language version.

refsWebsite

Global rank Hebrew rank

4^th place

18^th place

2^nd place

10^th place

447^th place

285^th place

1^st place

6^th place

406^th place

621^st place

28^th place

71^st place

68^th place

170^th place

cnn.com

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael Irizarry, Lynn D. Kramer, Takeshi Iwatsubo, Lecanemab in Early Alzheimer's Disease, The New England Journal of Medicine 388, 2023-01-05, עמ' 9–21 doi: 10.1056/NEJMoa2212948 (באנגלית)
Emily Harris, FDA Greenlights Second Alzheimer Drug, Donanemab, JAMA, 2024-07-26 doi: 10.1001/jama.2024.13386 (באנגלית)

סוכנות התרופות האירופית, Leqembi | European Medicines Agency (EMA), www.ema.europa.eu, ‏2024-07-26 (באנגלית)

"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment" (הודעה לעיתונות). U.S. Food and Drug Administration (FDA). 6 בינואר 2023. נבדק ב-7 בינואר 2023. {{cite press release}}: (עזרה)
"FDA Grants Accelerated Approval for Alzheimer's Disease Treatment" (הודעה לעיתונות). U.S. Food and Drug Administration (FDA). 6 בינואר 2023. נבדק ב-7 בינואר 2023. {{cite press release}}: (עזרה)

"Lecanemab Summary Review" (PDF). Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration. ארכיון (PDF) מ-7 בינואר 2023. נבדק ב-7 בינואר 2023. {{cite web}}: (עזרה)

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael Irizarry, Lynn D. Kramer, Takeshi Iwatsubo, Lecanemab in Early Alzheimer's Disease, The New England Journal of Medicine 388, 2023-01-05, עמ' 9–21 doi: 10.1056/NEJMoa2212948 (באנגלית)
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy. 6 (2): 16. doi:10.1186/alzrt246. PMC 4054967. PMID 25031633.
Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, et al. (במרץ 2018). "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation. 15 (1): 98. doi:10.1186/s12974-018-1134-4. PMC 5875007. PMID 29592816. {{cite journal}}: (עזרה)
Emily Harris, FDA Greenlights Second Alzheimer Drug, Donanemab, JAMA, 2024-07-26 doi: 10.1001/jama.2024.13386 (באנגלית)

"Lecanemab Summary Review" (PDF). Center for Drug Evaluation and Research (CDER). U.S. Food and Drug Administration. ארכיון (PDF) מ-7 בינואר 2023. נבדק ב-7 בינואר 2023. {{cite web}}: (עזרה)